Navigation Links
ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD)
Date:9/21/2010

lin resistance.

CCX140 is chemically distinct from all other known antagonists of CCR2 and works by blocking the monocyte/macrophage infiltration that occurs during inflammation and thus is designed to provide selective treatment of the disease without compromising other immune functions.

About ChemoCentryx

ChemoCentryx, Inc., is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a biological network that regulates inflammation via a collection of secreted chemokine molecules, or ligands, and their specific cell surface receptors. Based on its proprietary drug discovery and drug development platform, ChemoCentryx has internally generated multiple clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. ChemoCentryx's lead compound, Traficet-EN, a specific CCR9 antagonist, completed a Phase II/III multi-national clinical trial, called PROTECT-1, in patients with moderate-to-severe Crohn's disease, where it demonstrated the ability to induce a clinical response and to maintain clinical remission over the course of the trial.  Phase III clinical trials of Traficet-EN are expected to initiate in the fourth quarter 2010.  In addition, CCX025, also a CCR9 antagonist, has successfully completed a Phase I clinical program. Other clinical programs include CCX140, which targets the CCR2 receptor, in Phase II clinical development for the treatment of type 2 diabetes mellitus; CCX354, a CCR1 antagonist in a Phase II clinical trial for the treatment of rheumatoid arthritis; and CCX168, a C5aR antagonist, in Phase I clinical development. ChemoCentryx also has several programs in preclinical development. ChemoCentryx is private
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
2. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
3. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
4. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
5. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
6. ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
7. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
8. ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohns Disease at the Digestive Disease Week (DDW) 2010 Conference
9. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
10. Spherix Reports Second Quarter Earnings
11. Tapestry Reports Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  Zafgen, Inc., a leading biopharmaceutical company dedicated ... patients, today announced initial results from its Phase ... methionine aminopeptidase 2 (MetAP2), in patients with Prader-Willi ...  These results showed improvements in body weight, hunger-related ...
(Date:1/14/2014)... BEVERLY HILLS, Calif. , Jan. 14, 2014 The Brandeis ... Los Angeles a premier and affordable laser tattoo ... treatment special. Dr. Brandeis, focus is in providing high quality cosmetic ... to all patients. " Southern California ...
(Date:1/14/2014)... , Jan. 14, 2014 NineSigma , Inc., ... its Innovation Leadership Summit , May 14-16, 2014 ... Cleveland Ohio . This ... organizations committed to breakthrough achievements through open innovation. Participants ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4
(Date:4/18/2014)... Medicine researchers have been awarded two-year grants for their ... this month. Of the 110 initial submissions to the ... Program, only four projects were funded, three of which ... Powell, M.D., Ph.D.; G. William Wong, Ph.D.; and Elias ... of oncology, will use his $500,000 proof of principle ...
(Date:4/18/2014)... Calif. (April 18, 2014) ― A new study in ... weekly patterns in health-related Google searches reveals a recurring ... strategies. , Investigators from San Diego State ... the Monday Campaigns, analyzed "healthy" Google searches (searches that ... "healthy diet") originating in the U.S. from 2005 to ...
(Date:4/17/2014)... in non-cancerous prostate tissue may have nearly twice the ... no inflammation, according to results of a new study ... Center. , The link between persistent inflammation and cancer ... cancer those with a Gleason score between 7 ... aggressive and rapidly growing prostate cancers. , "What we,ve ...
(Date:4/17/2014)... today in PLOS Pathogens , children who live ... can mount an immune response to infection with malaria ... of high fever and illness and partially control the ... may help researchers develop future interventions that prevent or ... Each year, approximately 200 million cases of malaria occur ...
(Date:4/17/2014)... published in the April issue of Immunity , ... for Medical Research, says it,s time to take a ... treating sepsis, which kills millions worldwide every year, ... molecules released into the bloodstream to fight an injury ... necessary for maintaining good health without inflammation, wounds ...
Breaking Medicine News(10 mins):Health News:New research shows people are thinking about their health early in the week 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2
... Jan. 5 MDdatacor, Inc., a leader in ... care providers, today,announced a new contract with Summa ... System, one of the largest,organized delivery healthcare systems ... initiative with two national insurers and one regional ...
... , MINNEAPOLIS, Jan. 5 General Mills, NBC,s The Biggest ... launch the Pound For Pound Challenge, an initiative that encourages ... pound dieters pledge to lose this new year, a pound ... and more people need help getting food on the table ...
... Diet! reduced dangerous,visceral belly fat on average by 33% ... Yale University Prevention Research Center at Griffin ... the plan and tracked their,progress using cross-sectional MRI scans ... to decrease risk factors for heart health such as,cholesterol, ...
... announced the,first implants of the Full Sense(TM) Device on November ... Randal Baker MD, James Foote MD,and Mexican doctor Jorge Trevino ... is a stent like device placed through the mouth into,the ... It causes fullness by,placing pressure on the bottom of ...
... 5 With the economy in a,state of decline, it ... doctors are down 10 percent to 15 percent and many ... are certain measures,that can be taken to lessen the burden ... While many individuals are dealing with cutbacks, it is important ...
... Jan. 5 Hurricane Ike devastated the,Texas coast on ... surrounding cities are still without shelter. With the help ... now living in tents will be,able to stay warm ... On November 29, Brady Spears, Equal Health CEO ...
Cached Medicine News:Health News:Summa Health Network Announces Contract with MDdatacor to Support Multi-Insurer Health Care Quality Initiative; Initiative to Use Clinical Data to Supplement Claims Data and Enhance Outcomes 2Health News:Summa Health Network Announces Contract with MDdatacor to Support Multi-Insurer Health Care Quality Initiative; Initiative to Use Clinical Data to Supplement Claims Data and Enhance Outcomes 3Health News:General Mills, NBC's The Biggest Loser and Feeding America Partner to Launch Pound For Pound Challenge 2Health News:General Mills, NBC's The Biggest Loser and Feeding America Partner to Launch Pound For Pound Challenge 3Health News:General Mills, NBC's The Biggest Loser and Feeding America Partner to Launch Pound For Pound Challenge 4Health News:General Mills, NBC's The Biggest Loser and Feeding America Partner to Launch Pound For Pound Challenge 5Health News:Photo: New Yale University Prevention Research Center Study Finds Flat Belly Diet! Reduced Dangerous Visceral Belly Fat by 33% 2Health News:Open Wide, It's Time to Lose Weight! 2Health News:Staying Healthy in a Tough Economy 2Health News:Staying Warm with the Help of Equal Health 2